BR112021021721A2 - Forma sólida de composto de diaminopirimidina ou hidrato do mesmo, método de preparação para a mesma e aplicação da mesma - Google Patents

Forma sólida de composto de diaminopirimidina ou hidrato do mesmo, método de preparação para a mesma e aplicação da mesma

Info

Publication number
BR112021021721A2
BR112021021721A2 BR112021021721A BR112021021721A BR112021021721A2 BR 112021021721 A2 BR112021021721 A2 BR 112021021721A2 BR 112021021721 A BR112021021721 A BR 112021021721A BR 112021021721 A BR112021021721 A BR 112021021721A BR 112021021721 A2 BR112021021721 A2 BR 112021021721A2
Authority
BR
Brazil
Prior art keywords
solid form
hydrate
preparation
application
diaminopyrimidine compound
Prior art date
Application number
BR112021021721A
Other languages
English (en)
Inventor
Cheungling Cheng
Hongjun Wang
Huai Huang
Jianmei Pang
Jie Meng
Kai Liu
Liying Zhou
Nana Tian
shenzhen Fu
Xichao Chen
Xuelian Liu
Yanan Liu
Yanping Zhao
Zewang Feng
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of BR112021021721A2 publication Critical patent/BR112021021721A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

forma sólida de composto de diaminopirimidina ou hidrato do mesmo, método de preparação para a mesma e aplicação da mesma. a presente invenção refere-se a uma forma sólida de 5-((2-etinil-5-isopropilpiridin-4-il)óxi)pirimidina-2,4-diamina ou um hidrato do mesmo, um método para preparar a forma sólida, uma composição farmacêutica compreendendo a forma sólida e uma utilização da forma sólida para a prevenção ou tratamento de uma doença modulada por antagonistas do receptor p2x3 e/ou p2x2/3.
BR112021021721A 2019-04-30 2020-04-29 Forma sólida de composto de diaminopirimidina ou hidrato do mesmo, método de preparação para a mesma e aplicação da mesma BR112021021721A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085207 2019-04-30
PCT/CN2020/087687 WO2020221275A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112021021721A2 true BR112021021721A2 (pt) 2021-12-28

Family

ID=73029662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021721A BR112021021721A2 (pt) 2019-04-30 2020-04-29 Forma sólida de composto de diaminopirimidina ou hidrato do mesmo, método de preparação para a mesma e aplicação da mesma

Country Status (12)

Country Link
US (1) US20220204475A1 (pt)
EP (1) EP3964505A4 (pt)
JP (1) JP2022530889A (pt)
KR (1) KR20220008284A (pt)
CN (1) CN113993858B (pt)
AU (1) AU2020265969A1 (pt)
BR (1) BR112021021721A2 (pt)
CA (1) CA3138234A1 (pt)
MX (1) MX2021013300A (pt)
SG (1) SG11202111907UA (pt)
TW (2) TWI806708B (pt)
WO (1) WO2020221275A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7207634B2 (ja) * 2017-11-01 2023-01-18 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
US20220177447A1 (en) * 2019-04-30 2022-06-09 Beijing Tide Pharmaceutical Co., Ltd. Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930135B (zh) * 2004-03-05 2011-12-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
BRPI0611375A2 (pt) * 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
JP4850911B2 (ja) * 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
BR112018068399A2 (pt) * 2016-03-14 2019-01-15 Afferent Pharmaceuticals Inc pirimidinas e variantes das mesmas e usos para as mesmas
MA44489A (fr) * 2016-03-25 2019-01-30 Afferent Pharmaceuticals Inc Pyrimidines et variants de celles-ci, et leurs utilisations
CN108778280B (zh) * 2016-11-07 2021-07-27 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的多晶型及其制备方法
PT3539545T (pt) * 2016-11-14 2021-09-06 Jiangsu Hengrui Medicine Co Forma cristalina de antagonista do recetor de gnrh e método para a preparação da mesma
JP2020502043A (ja) * 2016-12-22 2020-01-23 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド ４’−チオ−２’−フルオロヌクレオシドホスファミド化合物の固体形態及びそのための調製方法及びその使用
JP6230743B1 (ja) * 2017-05-31 2017-11-15 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の結晶
JP7207634B2 (ja) * 2017-11-01 2023-01-18 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
US10457740B1 (en) * 2018-01-29 2019-10-29 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using P2RX2 inhibitors
US20220177447A1 (en) * 2019-04-30 2022-06-09 Beijing Tide Pharmaceutical Co., Ltd. Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof

Also Published As

Publication number Publication date
US20220204475A1 (en) 2022-06-30
TWI806708B (zh) 2023-06-21
MX2021013300A (es) 2022-02-11
AU2020265969A1 (en) 2021-12-16
TW202106675A (zh) 2021-02-16
JP2022530889A (ja) 2022-07-04
SG11202111907UA (en) 2021-11-29
TWI773987B (zh) 2022-08-11
CN113993858A (zh) 2022-01-28
EP3964505A4 (en) 2022-12-21
EP3964505A1 (en) 2022-03-09
CN113993858B (zh) 2024-05-28
CA3138234A1 (en) 2020-11-05
WO2020221275A1 (zh) 2020-11-05
KR20220008284A (ko) 2022-01-20
TW202241864A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
CL2020000029A1 (es) Nuevos compuestos de carboxamida sulfonamida.
BR112017002001A2 (pt) compostos e composição farmacêutica
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EP4212532A3 (en) Mitragynine analogs and uses thereof
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
PH12019502033A1 (en) Pharmaceutical composition comprising selexipag
BR112021021721A2 (pt) Forma sólida de composto de diaminopirimidina ou hidrato do mesmo, método de preparação para a mesma e aplicação da mesma
JO2686B1 (en) Vehicles
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
PH12021551356A1 (en) Crystalline forms and salt forms of a kinase inhibitor
TN2017000158A1 (en) Carbazole derivatives
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
CO2019010510A2 (es) Composiciones farmacéuticas y métodos para tratar enfermedades cardiovasculares
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
BR112018009534A2 (pt) composição farmacêutica contendo 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi }-n-(metilsulfonil)acetamida
CY1113726T1 (el) Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
WO2020106461A3 (en) Anti-mertk antibodies and methods of use thereof
EA201890525A1 (ru) Кристаллическая форма 2-(2,6-дихлорфенил)-1-[(1s,3r)-3-(гидроксиметил)-5-(3-гидрокси-3-метилбутил)-1-метил-3,4-дигидроизохинолин-2(1h)-ил]этанона для лечения болезни паркинсона
BR112015021097A2 (pt) formulações de compostos orgânicos
BR112015030171A2 (pt) composto, composição farmacêutica, método para prevenir ou tratar uma doença ou seus sintomas, uma afecção ou um distúrbio mediado parcial ou completamente por receptores nicotínicos de acetilcolina, uso de 4-(5-(4- clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il) benzenossulfonamida